Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.

Abstract

Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.

• Authors: Khurum H Khan, Audrey Fenton, Eimer Murtagh, James J A McAleer, Alison Clayton
• Journal: Tumori (Tumori) 2012 Sep-Oct Vol. 98 Issue 5 Pg. 139e-142e ISSN: 2038-2529 [Electronic] United States
• PMID: 23235770 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Indoles
• Pyrroles
• Sunitinib

Topics

• Angiogenesis Inhibitors (administration & dosage, adverse effects)
• Brain (pathology)
• Carcinoma, Renal Cell (drug therapy, secondary)
• Diagnosis, Differential
• Female
• Headache (etiology)
• Humans
• Indoles (administration & dosage, adverse effects)
• Kidney Neoplasms (drug therapy, pathology)
• Magnetic Resonance Imaging
• Middle Aged
• Posterior Leukoencephalopathy Syndrome (chemically induced, complications, diagnosis, pathology)
• Pyrroles (administration & dosage, adverse effects)
• Seizures (etiology)
• Sunitinib